秋水仙碱预防与COVID-19疫苗接种后痛风发作减少相关
在青岛大学附属医院痛风门诊开展的一项基于临床就诊人群的横断面研究,纳入549例痛风患者(中位年龄39岁,84.2%已接种疫苗)。接种COVID-19疫苗者3个月内痛风发作风险升高(调整OR 6.02;95%CI 3.00至12.08),秋水仙碱使用与疫苗接种后痛风发作可能性降低47%相关。
要点
- 接种COVID-19疫苗者3个月内痛风发作风险升高,调整OR 6.02(95%CI 3.00至12.08)。
- 多数发作出现在第一剂(99/119,83.2%)或第二剂(70/115,60.9%)接种后1个月内。
- 秋水仙碱使用与疫苗接种后痛风发作可能性降低47%相关。
核心结论
- COVID-19疫苗接种与痛风发作风险升高相关,发作主要出现在每剂疫苗接种后第1个月,且与秋水仙碱预防呈负相关。
研究设计与样本
- 2021年2月至10月在青岛大学附属医院痛风门诊开展的基于临床就诊人群的横断面研究,采用系统随机抽样方法从痛风随访患者中选择研究对象。
- 共纳入549例痛风患者,中位年龄39岁,84.2%已接种疫苗;其中462例接种了COVID-19疫苗。
- 通过访谈、健康码和病历收集疫苗接种及潜在危险因素数据,采用逻辑回归调整协变量。
主要发现
- 462例接种COVID-19疫苗的患者中,203例(43.9%)在接种后3个月内出现至少一次痛风发作。
- 多数发作出现在第一剂接种后1个月内(99/119,83.2%)或第二剂接种后1个月内(70/115,60.9%)。
- 与未接种者相比,COVID-19疫苗接种与3个月内痛风发作风险升高相关(调整OR 6.02;95%CI 3.00至12.08)。
- 秋水仙碱使用与疫苗接种后痛风发作可能性降低47%相关。
关键数值与推荐
- COVID-19疫苗接种者3个月内痛风发作的调整OR为6.02(95%CI 3.00至12.08)。
- 秋水仙碱使用与疫苗接种后痛风发作可能性降低47%相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: COVID-19 vaccination often triggers a constellation of transitory inflammatory symptoms. Gout is associated with several comorbidities linked to poor outcomes in COVID-19, and gout flares can be triggered by some vaccinations. We analysed the risk of gout flares in the first 3 months after COVID-19 vaccination with inactivated virus, and whether colchicine can prevent gout flares following post-COVID-19 vaccination. METHODS: A clinical delivery population-based cross-sectional study was conducted in the Gout Clinic at the Affiliated Hospital of Qingdao University between February and October 2021. Study participants were selected using a systematic random sampling technique among follow-up patients with gout. We collected data, including vaccinations and potential risk factors, using a combination of interviews, health QR codes and medical records. Logistic regression was used to adjust for covariates. RESULTS: We enrolled 549 gout participants (median age 39 years, 84.2% vaccinated). For the 462 patients who received COVID-19 vaccine, 203 (43.9%) developed at least one gout flare in the 3 months after vaccination. Most of these flares were experienced within 1 month after the first (99/119 (83.2%)) or second (70/115 (60.9%)) dose of vaccine. Compared with unvaccinated participants, COVID-19 vaccination was associated with higher odds of gout flare within 3 months (adjusted OR 6.02; 95% CI 3.00 to 12.08). Colchicine use was associated with 47% less likelihood of postvaccine gout flare. CONCLUSION: COVID-19 vaccination was associated with increased odds of gout flare, which developed mainly in month 1 after each vaccine dose, and was negatively associated with colchicine prophylaxis.
引用
- Lu J, He Y, Terkeltaub R, et al. Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination. Ann Rheum Dis. 2022. PMID: 35277390. doi:10.1136/annrheumdis-2022-222199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。